Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial

• Status: Completed
• Trial end date: 2018-12-21
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find out whether postoperative delirium can be more properly prevented by the combination of determined preventive agents in past studies. Further on the investigators measure pre- and postoperative cortisol, neuron specific enolase (NSE) and S-100beta levels.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Basel, Switzerland
• Collaborator: Kantonsspital Baden
• Treatments: Anesthetics; Haloperidol; Haloperidol decanoate; Ketamine

Criteria

Inclusion Criteria:

• Age 65 years and older

• Signed agreement

Exclusion Criteria:

• Delirium at admittance or MMSE score <24 points

• High risk for postoperative ICU treatment

• Haloperidol or Ketamine intolerance

• Risk of lack of cooperation

• Drug an alcohol abuse

• Dementia

• QT interval (QTc) prolongation (at least 460ms in men, at least 470ms women) or drugs influencing QT interval, such as class Ia and III antiarrhythmics, Gatifloxacin, Moxifloxacin, Pentamidin, Cotrimoxazol, Tacrolimus, Dolasetron

• Parkinson's disease

• Intake of dopaminergic drugs (Levodopa, dopamine agonists)

• Parkinsonism

• Epilepsy

• Unable to be interviewed (severe Dementia, speaking disorders, intubation, respiratory isolation, aphasia, coma, terminal illness)

• Delay of operation of more than 72 hours past hospital admittance

• Body weight >100kg